“VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 9, no. 5, Sept. 2017, pp. 224-7, https://doi.org/10.25004/IJPSDR.2017.090504.